Current treatment options for age-related macular degeneration
Authors:
Schreiberová Zuzana; Karhanová Marta; Pašková Barbora
Authors‘ workplace:
Oční klinika, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice Olomouc
Published in:
Geriatrie a Gerontologie 2023, 12, č. 4: 172-176
Category:
Review Article
Overview
Age-related macular degeneration (AMD) is a degenerative disease of the retina that affects its central region, the macula lutea. It is a severe, sight-threatening disease that initially manifests unilaterally in most cases, but half of patients develop involvement of the fellow eye within 5 years of diagnosis. The etiology is multifactorial, with risk factors including age, genetic predisposition, smoking, and status post cataract surgery. There are 2 forms of the disease, namely dry and wet. The dry form of AMD usually progresses slowly, whereas the wet form can rapidly lead to deterioration of visual function. Diagnosis relies primarily on slit-lamp examination of the ocular background and examination by optical coherence tomography and angiography. The treatment of the dry form consists of supportive pharmacotherapy or rheopheresis, while the first-line treatment of the wet form is anti-vascular endothelial growth factor drugs, which are injected directly into the vitreous cavity. There is no prevention of the disease; regular examinations by an ophthalmologist and self-monitoring of vision using the so-called Amsler grid, which is used to detect early signs of the disease, are advisable.
Sources
1. Kuchynka P. Oční lékařství. Praha: Grada Publishing 2016; 936.
2. Vyawahare H, Shinde P. Age-related macular degeneration: epidemiology, pathophysiology, diagnosis, and treatment. Cureus 2022; 14(9): e29583.
3. Salmon JF. Kanski’s clinical ophthalmology. 9th ed. Oxford: Elsevier Books 2020; 956.
4. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31.
5. Hobbs SD, Pierce K. Wet age-related macular degeneration (Wet AMD). In: StatPearls [online]. Jan 2023 [cit. 2023-10-01]. Dostupné z: https://www.ncbi.nlm.nih.gov/books/NBK572147.
6. National Eye Institute. AREDS 2 Supplements for Age-Related Macular Degeneration (AMD) [online]. NEI 2021 [cit. 2023-10-05]. Dostupné z: https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration/nutritional-supplements-age-related-macular-degeneration.
7. Paříková A. Rheoferéza a její využití v léčbě chorob s poruchou mikrocirkulace. Přehled. Cesk Slov Oftalmol 2023; 79(1): 3–5.
8. Langrová H, Bláha V, Dvořáková H, et al. Rheoferéza v léčbě věkem podmíněné makulární degenerace. Cesk Slov Oftalmol. 2023; 79(1): 8–24.
9. Blaha M, Lanska M, Tomšova H, et al. Apheresis data registration in WWA registry-10-year experience of our center. Transfus Apher Sci 2017; 56(5): 738–741.
10. European Medicines Agency. Příloha I: Souhrn údajů o přípravku [online]. EMA 2016 [cit. 2023-10-05]. Dostupné z: https://www.ema.europa.eu/documents/product-information/lucentis-epar-product-information_cs.pdf.
11. European Medicines Agency. Příloha I: Souhrn údajů o přípravku [online]. EMA 2017 [cit. 2023-10-05]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/eylea-epar-product-information_cs.pdf.
12. European Medicines Agency. Příloha I: Souhrn údajů o přípravku [online]. EMA 2020 [cit. 2023-10-05]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/beovu-epar-product-information_cs.pdf.
13. European Medicines Agency. Příloha I: Souhrn údajů o přípravku [online]. EMA 2022 [cit. 2023-10-05]. Dostupné z: https://www.ema.europa.eu/en/documents/product-information/vabysmo-epar-product-information_cs.pdf.
14. Tyfloservis. Základní informace pro klienty [online]. Tyfloservis 2020 [cit. 2023-09-30]. Dostupné z: https://www.tyfloservis.cz/informace-pro-klienty.
15. Amsler grid. In: drsharangwartikar.com [online]. Sharang Wartikar 2020 [cit. 2023-09-30]. Dostupné z: https://drsharangwartikar.com/wp-content/uploads/I-Amslers-grid.png.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2023 Issue 4
Most read in this issue
- Gerontological prevention as part of geriatrics
- Differenciation of palliative care phases of nursing home clients – introduction of a new questionnaire
- The influence of selected factors on the attributed dignity of hospitalized elderly
- The role of the doctor in cases of domestic violence against the elderly